Patents by Inventor Danny Gauvreau

Danny Gauvreau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of an orexin receptor antagonist
    Patent number: 8674093
    Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: March 18, 2014
    Assignees: Merck Canada Inc., Merck Sharp & Dohme Corp.
    Inventors: Louis-Charles Campeau, John Y. Chung, Danny Gauvreau, Melina Girardin-Rondeau, Gregory Hughes, Kevin M. Maloney, Christophe Mellon, Jeffrey C. Moore, Paul O'Shea, Stephane Ouellet
  • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    Publication number: 20130296382
    Abstract: Heteroaromatic compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: July 3, 2013
    Publication date: November 7, 2013
    Inventors: Jason Burch, Bernard Cote, Natalie Nguyen, Chun Sing Li, Miguel St-Onge, Danny Gauvreau
  • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    Publication number: 20110245296
    Abstract: Heteroaromatic compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: March 28, 2011
    Publication date: October 6, 2011
    Inventors: Jason Burch, Bernard Cote, Natalie Nguyen, Chun Sing Li, Miguel St-Onge, Danny Gauvreau
  • Process for the Preparation of an Orexin Receptor Antagonist
    Publication number: 20110165632
    Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 18, 2009
    Publication date: July 7, 2011
    Inventors: Louis-Charles Campeau, John Y. Chung, Danny Gauvreau, Melina Girardin-Rondeau, Gregory Hughes, Kevin M. Maloney, Christophe Mellon, Jeffrey C. Moore, Paul O'Shea, Stephane Quellet